AFter FDA Rejection, TransEnterix Could Turn Focus to Other Surgery Robot
As medical device developer TransEnterix, Inc. (NYSE MKT: TRXC) gathers itself from a blow dealt Wednesday by the U.S. Food and Drug Administration, analysts predict the company will shift focus from one surgical robot to another.
On Wednesday afternoon, FDA denied an application by TransEnterix to market its SurgiBot System surgical tool, a medical device that would be used to help doctors during minimally invasive surgeries. The disclosure sent shares tumbling more than 50 percent overnight.
On Wednesday afternoon, FDA denied an application by TransEnterix to market its SurgiBot System surgical tool, a medical device that would be used to help doctors during minimally invasive surgeries. The disclosure sent shares tumbling more than 50 percent overnight.